AVIEW LCS vs Mindbowser AI Cardiovascular Risk Prediction

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AVIEW LCS

by Coreline Soft

Mindbowser AI Cardiovascular Risk Prediction

by Mindbowser

AI Verdict

AVIEW LCS is an AI-powered diagnostic imaging solution that analyzes CT scans for lung conditions and provides coronary artery calcification (CAC) scoring. Mindbowser AI Cardiovascular Risk Prediction, conversely, focuses on broader cardiovascular risk prediction and clinical decision support, likely leveraging diverse patient data from EHR systems. While both contribute to cardiovascular health assessment, AVIEW LCS specializes in image-based quantification, whereas Mindbowser offers a more comprehensive, data-driven risk prediction model.

Choose AVIEW LCS if…

Choose AVIEW LCS if your primary need is a comprehensive, AI-driven platform for detailed analysis of lung nodules, COPD, and coronary artery calcification directly from low-dose CT scans. This tool is ideal for radiology departments and pulmonology practices requiring automated detection, quantification, and longitudinal comparison of findings to enhance diagnostic accuracy and streamline reporting workflows.

View AVIEW LCS →

Choose Mindbowser AI Cardiovascular Risk Prediction if…

Choose Mindbowser AI Cardiovascular Risk Prediction if your organization seeks to integrate advanced AI-powered cardiovascular risk assessment directly into your existing EHR systems for clinical decision support and population health initiatives. This solution is best suited for providers and hospitals aiming to leverage compliant, interoperable AI to proactively identify at-risk patients within their primary care and cardiology workflows.

View Mindbowser AI Cardiovascular Risk Prediction →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AVIEW LCS	Mindbowser AI Cardiovascular Risk Prediction
Pricing	Subscription or one-off payment	Contact for pricing
Deployment	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)	Cloud-based
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Unknown
HIPAA	Yes AI-estimated	Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AVIEW LCS	Mindbowser AI Cardiovascular Risk Prediction
Name	AVIEW LCS	Mindbowser AI Cardiovascular Risk Prediction
Company	Coreline Soft Co.	Mindbowser
Tagline	AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment	We bridge technology & compassion to build smarter, compliant, patient-centered care.
Categories	Cardiology AI, Oncology AI, Radiology & Imaging AI	Cardiology AI
Key Features	Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass), Automated comparison of nodules in follow-up CT scans, Comprehensive, automated report generation, Integration with PACS/RIS and third-party platforms	AI Cardiovascular Risk Prediction, AI-powered automation, HIPAA and SOC 2 compliance, EHR integration (Epic, Cerner, Athenahealth, FHIR), Clinical Decision Support System, Data & Analytics, HL7 & FHIR interoperability, Secure, compliant healthcare data access

Videos

Demos, reviews, and walkthroughs featuring AVIEW LCS and Mindbowser AI Cardiovascular Risk Prediction.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications and conditions each tool is designed to address?

AVIEW LCS is an AI-powered solution focused on the detection and analysis of lung nodules for lung cancer screening, COPD, and coronary artery calcification from low-dose CT scans. Mindbowser AI Cardiovascular Risk Prediction is designed for providers and hospitals to assess general cardiovascular risks.

What type of patient data or imaging modalities do these tools utilize for their analysis?

AVIEW LCS performs integrated, fully automatic analysis from a single low-dose CT scan. Mindbowser AI Cardiovascular Risk Prediction integrates with leading EHR systems, implying it utilizes patient data from these systems for its risk prediction.

How do these tools specifically contribute to cardiovascular assessment, and what metrics do they provide?

AVIEW LCS provides Coronary Artery Calcification (CAC) scoring, including Agatston, volume, and mass, from CT scans. Mindbowser AI Cardiovascular Risk Prediction offers general AI-powered cardiovascular risk prediction as part of its clinical decision support system.

What are the integration capabilities of each tool with existing clinical systems?

AVIEW LCS offers integration with PACS/RIS and other third-party platforms. Mindbowser AI Cardiovascular Risk Prediction integrates with leading EHR systems such as Epic, Cerner, Athenahealth, and supports HL7 & FHIR interoperability.

What regulatory clearances and compliance certifications do these tools hold?

AVIEW LCS has FDA clearance, is HIPAA compliant, and has a Business Associate Agreement (BAA). Mindbowser AI Cardiovascular Risk Prediction is HIPAA compliant with a BAA and also holds SOC 2 compliance.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform